Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belvarafenib alone or with Cobimetinib/Nivolumab in NRAS-Mutant Advanced Melanoma
NCT04835805Phase 1Active, not recruiting
- Sponsor
- Genentech
- Start
- May 2021
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label trial of Belvarafenib in melanoma (3 arms), sponsored by Genentech. Primary endpoints: Dose Limiting Toxicity at 28 Days and Adverse Events up to 4 Years. Started May 2021; status: active, not recruiting.
02
Drugs
Belvarafenib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04835805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04835805.